A 27-year-old man with aplastic anemia and renal insufficiency requiring dialysis underwent allogeneic PBSCT. The preparative regimen consisted of melphalan, ATG and TLI. GVHD prophylaxis consisted of cyclosporine and prednisolone. He was dialyzed prior to administration of melphalan and at 24 and 72 h after it. Otherwise, the dialysis schedule was unchanged, at three times a week. Engraftment was rapid. Regimen-related toxicity was minimal. Pharmacokinetic parameters of melphalan were not significantly altered with its plasma half-life 1.5 h. Patients with renal failure can receive allogeneic HSCT, and a combination of melphalan, ATG and TLI may serve as an alternative to CY and ATG.
Aplastic anemia is a rare hematological disease, which is characterized by pancytopenia and a marrow parenchyma that is lacking hematopoietic elements. Most patients with severe aplastic anemia die of infection or hemorrhage without definitive and/or supportive therapy. Effective therapies for aplastic anemia consist of immunosuppressive therapy using cyclosporine, anti-human thymocyte immunoglobulin (ATG), and allogeneic hematopoietic stem cell transplantation (HSCT). HSCT from an HLA-identical sibling potentially cures the underlying bone marrow failure. Survival rates as high as 90% have been reported from a single wellexperienced institution, 1 and of 75-80% for registry data, which reflect more general experience. HSCT is a promising modality for patients with AA, yet it is frequently avoided or delayed in candidates with abnormal renal function, because the pharmacokinetics and/or pharmacodynamics of high-dose chemotherapy may be altered in these patients. Especially when recipients receive regular dialysis, it is quite difficult to adjust the dose of anticancer drugs used in the preparative regimen. In this report, we describe the clinical course of a patient with renal failure requiring hemodialysis who was successfully transplanted from his HLA-identical sibling for the treatment of aplastic anemia. The patient received melphalan, ATG and total lymph node irradiation (TLI) as the preparative regimen. The pharmacokinetics of high-dose melphalan are also presented.
Case report
A 27-year-old man with severe aplastic anemia was transferred to our hospital for allogeneic peripheral blood stem cell transplantation (PBSCT). He was diagnosed as having acquired aplastic anemia at the age of 19, of which the etiology was unknown. The patient presented with severe pancytoenia (hemoglobin of 3.4 g/dl, platelets count of 28 000/mm 3 , neutrophils of 1300/l, and reticulocytes of 1.3%). He had received multiple red cell transfusions, the total amount of transfused red cells reaching 100 U.
He had dialysis-dependent end-stage renal disease secondary to Henoch-Schonelin purpura nephritis, occurring 13 years before the diagnosis of severe aplastic anemia. He had been on a stable dialysis schedule (three times a week). Except for chronic renal failure and AA, he was in good physical condition at the time of referral for transplantation. Pre-transplant examination showed normal cardiac, respiratory and endocrine function. Before transplantation, serum levels of creatinine and BUN were 990 mol/l and 43.5 mmol/l, respectively. Creatinine clearance could not be examined because of anuria.
The patient was offered the option of allogeneic PBSCT after extensive discussion of the potential benefits, risks and alternatives. Potential concerns discussed with the patient included possible graft failure from the lack of immunosuppressive effect if anti-cancer drugs and their metabolites were too rapidly cleared by dialysis or failure to engraft or severe melphalan-related toxicity if hemodialysis clearance was poor. The PBSCT process proceeded with the patient's consent and was approved by the Institutional Review Board.
He underwent allogeneic PBSCT from his HLA-identical sister in June 2001. The preparative regimen consisted of 60 mg/m 2 melphalan, horse ATG 15 mg/kg for 3 days and TLI 4.0 Gy in 2 fractions for 1 day. GVHD prophylaxis consisted of a combination of oral cyclosporine 6 mg/kg starting on day Ϫ2, and prednisolone at a dosage of 0.5 mg/kg/day from day 7. He received 4.0 ϫ 10 6 /kg CD34-positive cells. The use of most antibiotics such as quinolones, fluconazole, cephems and aminoglycosides in patients with renal dysfunction has already been established, and we administered these drugs as reported previously. We determined the blood levels of cyclosporine three times a week, and adjusted the dosage. Blood levels of cyclosporine were well controlled throughout the clinical course.
The patient was dialyzed prior to the administration of melphalan and then at 24 and 72 h after it. Otherwise, the dialysis schedule was unchanged, at three times a week throughout the clinical course. A right internal jugular double-lumen temporary vascular catheter was used for dialysis until day 27. Thereafter, an arteriovenous shunt in the left arm was used for blood access. Dialysis was performed with a PS-1.9uw dialyzer (Kawasumi, Tokyo, Japan), using bicarbonate dialysis, with a dialysate flow of 500 ml/min and a blood flow rate between 160 ml/min and 200 ml/min.
His clinical course was uneventful. He tolerated the preparative regimen well, and drug-related toxicity was minimal. He developed only grade I mucositis. 3 Hepatic venoocclusive disease (VOD), the dose-limiting toxicity of highdose melphalan, 4 did not develop. The neutrophil count reached 500/l on day 9. The platelet count reached 20 000/l on day 11. He received red cell transfusions on days 1, 4 and 7, and platelet transfusions on days 1, 4, 7 and 9. Full donor chimerism was confirmed on day 13 by fluorescence in situ hybridization analysis using blood samples. Neither GVHD nor infection occurred. He was discharged from hospital on day 29. His complete blood count gradually increased to normal levels with a hemoglobin of 10.0 g/dl and a platelet of 200 000/l. He did not need any transfusions for 5 months. He has not developed either late infection or chronic GVHD, although prednisolone was stopped and cyclosporine has been tapered gradually. At present, 6 months after PBSCT, he is in good condition except for the renal failure. His clinical course is shown in Figure 1 .
Pharmacokinetic study of melphalan
The patient is 176 cm in height, 53.3 kg dry weight, and 1.66 m 2 body surface area. We administered melphalan at 60 mg/m 2 intravenously just after dialysis. It was infused for exactly 20 min using an infusion pump. Heparinized blood samples (5 ml) were drawn through a peripheral venous cannula up to 24 h after each initial dose at the following times: 10, 20, 30, 40, 50, 60, 90 min and 2, 3, 5, 9 and 24 h. Plasma was promptly separated and stored at Ϫ80°C. Plasma levels of melphalan were determined by a HPLC method, as previously reported. 5 The method allows detection of about 20 mg/ml. Pharmacokinetic parameters were calculated with validated software, TOPFIT program, using two-compartment model.
The concentration vs time values were fitted to a twocompartment model. Pharmacokinetic parameters for melphalan were C max 5. 
Discussion
This case demonstrates that patients with renal failure requiring dialysis can receive HSCT safely, when the transplantation strategy and supportive cares are well designed. We paid much attention to the control of infection, especially nosocomial infections. All the medical staff on the ward were required to use contact-isolation precautions involving frequent hand washing, use of disposable gloves and isolation gowns when caring for this recipient. Reverse isolation precautions were practiced, and no visitors except for close family members were allowed. A strict strategy for controlling nosocomial infection seemed to be beneficial for preventing post-transplant infection in this patient. Another important concern is adjustment of drug dosages used for preparative regimens. HSCT recipients usually receive multiple agents such as anti-cancer agents, antibiotics and immunosuppressive agents. If anti-cancer drugs and their metabolites are too rapidly cleared by dialysis, lack of immunosuppression might lead to graft failure, or, if hemodialysis clearance is poor, severe regimenrelated toxicity might occur. We chose the combination of melphalan, ATG and TLI as the preparative regimen in this patient, because the combination is highly immunosuppressive and is not influenced by recipient renal function. His clinical course revealed some important issues concerning HSCT for patients with aplastic anemia or those with renal dysfunction.
Firstly, this case shows that a preparative regimen without CY can be an alternative in aplastic anemia. CY was introduced into the clinical practice of marrow transplantation in 1970, and has remained a major component of many transplantation protocols.
1,2 At present, the combination of CY and ATG has become the standard preparative regimen for aplastic anemia. Storb et al 1 recently reported their data using this approach in 94 patients who experienced a rejection incidence of 4% and a survival rate of 88%. However, we excluded CY from the preparative regimen because little information is available concerning its pharmacokinetics in renal insufficiency and we considered that CY might be toxic for patients with renal failure. Bramwell et al 6 reported that the alkylating activity of CY is influenced more by the wide individual variation in CY breakdown than by decreased renal function. Grochow et al 7 failed to show any correlation between the severity of renal insufficiency and hematopoietic toxicity. In general, adjusting CY doses in the presence of renal failure has not been recommended. 8 However, there are some reports on fatal complications associated with CY in patients with renal failure. We previously experienced a patient with renal failure who developed life-threatening myopericarditis after receiving high-dose CY. 9 Serial serum concentrations of CY metabolites were persistently much higher than those in a myeloma patient with normal renal function. These findings indicate that CY might be toxic in the presence of renal dysfunction. Furthermore, potential cardiac insufficiency existed in this patient, because he had received a large number of blood transfusions. High-dose CY usually needs some hydration as well as intravenous Mesna to prevent hemorrhagic cystitis. We could not predict whether the patient would tolerate hydration, and therefore avoided high-dose CY.
Secondly, the combination of ATG, TLI and melphalan is a novel preparative regimen for aplastic anemia. All have profound immunosuppressive properties, and seem to be safe and convenient for patients with renal insufficiency. ATG is a polyclonal immunoglobulin prepared by injecting horses with human thymocytes. These horse antibodies are capable of destroying human leukocytes. It has been widely used with safety for patients with renal failure such as those undergoing renal transplantation. 10 Because its molecular weight is approximately 150 000, the moiety is not eliminBone Marrow Transplantation ated by dialysis. ATG does not require dose adjustment even in patients with renal failure. TLI, which involves extensive, fractionated irradiation of lymphoid organs with shielding of hematopoietic tissue, has been used for induction of chimerism in rodent models. 11 TLI combined with anti-T cell antibodies is effective in inducing tolerance to organ allografts in animals. 12 The advantage of using TLI for immunosuppression is that much normal tissue outside the field can be spared, and that recipient renal function does not influence effect and toxicity of TLI. Chan et al 13 demonstrated that a fludarabine-based non-myeloablative regimen was sufficiently immunosuppressive to engraft patients with severe aplastic anemia from an HLA-mismatched family donor or matched unrelated donor. Considering that rejection is the main problem in HSCT for aplastic anemia, we added melphalan to TLI and ATG for cytoreduction. Melphalan is often utilized for preparative regimens before HST. 14, 15 The combination of fludarabine with melphalan was originally described by the MD Anderson group. 16 However, Kottaridis et al 15 used a different dose of melphalan with in vivo CAMPATH-1H as conditioning. This non-myeloablative preparative regimen is relatively safe in a group of patients with high-risk features.
Lastly, it is to be noted that the pharmacokinetic parameters of melphalan were not significantly altered in this patient, and that the regimen-related toxicity was mild with only grade I mucositis. These findings indicate that melphalan can be safely used in patients with renal failure requiring dialysis. It is well known that melphalan is extensively bound to plasma proteins (approximately 90%), 17 and that little is eliminated by dialysis. 18 Thus, high-dose therapy has been given in patients with multiple myeloma and significantly compromised renal function, 18, 19 especially in the setting of autologous HSCT. 20, 21 However, use of high-dose melphalan has never been reported in the setting of allogeneic HSCT for patients with renal dysfunction, and the safety of high-dose melphalan remains unknown in these patients. However, this case demonstrates that the pharmacokinetic parameters of melphalan are not significantly altered in patients undergoing allogeneic HSCT as is the case with autologous HSCT. High-dose melphalan can be used safely in the preparative regimen before allogeneic HSCT, even when renal dysfunction exists in recipients. Because of the development of nonmyeloablative preparative regimens, older patients become candidates for allogeneic HSCT. Renal dysfunction can be a frequent problem in these patients. Melphalan should be included in the list of preparative regimens in recipients with renal dysfunction.
In conclusion, patients with severe renal failure requiring dialysis can receive allogeneic HSCT without any major adverse events, when the transplantation strategy and supportive care are designed well. The combination of melphalan, ATG and TLI may serve as a good alternative to CY and ATG in patients with renal failure undergoing allogeneic HSCT for the treatment of aplastic anemia.
